Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 11/20 | 0.41 |
| ▸ | KMO | O15229 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27267930 | 0.86 | SCN9A (0.46) | FFAR4SCN9A | |
| SCHEMBL5241392 | 0.86 | CNR2 (0.38) | HTR2CHTR2BCNR2KMOFFAR4 | |
| SCHEMBL30780907 | 0.86 | SCN9A (0.46) | FFAR4SCN9A | |
| SCHEMBL23909099 | 0.86 | CNR2 (0.38) | HTR2CHTR2BCNR2KMOSCN9A | |
| SCHEMBL10003961 | 0.86 | CNR2 (0.38) | HTR2CHTR2BCNR2KMOFFAR4 | |
| SCHEMBL9873759 | 0.86 | FFAR4 (0.44) | HTR2CHTR2BFFAR4SCN9A | |
| SCHEMBL23915543 | 0.86 | CNR2 (0.40) | HTR2CHTR2BCNR2KMOFFAR4 | |
| SCHEMBL23966507 | 0.82 | KDM4E (0.39) | HTR2CHTR2B | |
| SCHEMBL23908848 | 0.80 | MAPT (0.45) | CNR2 | |
| SCHEMBL10003224 | 0.79 | SYK (0.48) | HTR2CHTR2BCNR2KMOFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | HTR2C 1276/4885HTR2B 503/4885CNR2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.